Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

20.55 -0.46 (-2.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
Analyst's Vote of Confidence: Arcturus' COVID-19 Vaccine Efforts Set to Pay Off in Japan and Beyond
HC Wainwright has upgraded Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) from Neutral to Buy with  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023
Via Benzinga
Unity Software, Tapestry, CIRCOR International And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping more than 300 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Arcturus Therapeutics: Q1 Earnings Insights
Via Benzinga
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Sprinklr, EVgo, Emergent BioSolutions And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Arcturus Therapeutics Stock Is Soaring Today
Investors liked what they heard in its Q4 update. 
Via The Motley Fool
Arcturus Therapeutics's Return On Capital Employed Insights
Via Benzinga
A Preview Of Arcturus Therapeutics's Earnings
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
Via Benzinga
RH, Semtech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Semtech Corporation (NASDAQ: SMTC) shares dipped 12.7% to $28.00 in... 
Via Benzinga
S&P 500 Up 1%; Bluebird Bio Shares Plummet
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 1% on Wednesday. The Dow traded up 0.74% to 32,632.35 while the NASDAQ rose 1.51% to 11,893.07. The S&P 500, also... 
Via Benzinga
Stocks Rise As Investors Bet On Bank Recovery
Stocks are swinging higher today, as bond yields retreat and Wall Street bets that the worst of the regional banking crisis is in the rearview mirror. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Arcturus Therapeutics Ltd. (NASDAQ: ARCT) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Nasdaq Rises 1%; US Pending Home Sales Increase In February
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Wednesday. The Dow traded up 0.58% to 32,580.89 while the NASDAQ rose 1.09% to 11,843.85. The S&P... 
Via Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million. 
Via Benzinga
Arcturus Therapeutics Stock Is Rising Wednesday: What's Going On?
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares are trading higher Wednesday after the company reported strong fourth-quarter results and provided an update on pipeline progress. 
Via Benzinga
US Stocks Open Higher, Dow Jumps Over 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.72% to 32,628.42 while the NASDAQ rose 1.33%... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares rose 36.7% to $0.1914 in pre-market trading after the company reported strong revenue and margin growth for the year ended 2022. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on! 
Via InvestorPlace
Cal-Maine Foods, Lululemon Athletica And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Arcturus Therapeutics Shares Are Moving Higher After Hours
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares are booming in Tuesday's after-hours session after the company reported fourth-quarter results and provided an update on  
Via Benzinga
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.